ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
Dow Jones
38,239.66
0.40%
Brent Oil
88.165
0.00%
Bitcoin
62,891.84
-1.33%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Adicet Bio Inc (ACET) Quote

Adicet Bio Inc

Adicet Bio Inc (ACET)

NASDAQ
1.68
-0.13
(-7.18%)
Closed April 27 4:00PM
Delayed by 15 minutes
1.73
0.05
(2.98%)
After Hours: 6:52PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.73
Bid
1.72
Ask
1.86
Volume
1,251,696
1.66 Day's Range 1.825
1.10 52 Week Range 7.50
Market Cap
98.415M
Previous Close
1.81
Open
1.81
Last Trade
2
@
1.7213
Last Trade Time
Financial Volume
$ 2,181,950
VWAP
1.7432
Average Volume (3m)
1,278,637
Shares Outstanding
43,164,522
Dividend Yield
-
PE Ratio
-0.69
Earnings Per Share (EPS)
-3.31
Revenue
-
Net Profit
-142.66M

About Adicet Bio Inc

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like ant... Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.adicetbio.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Adicet Bio Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ACET. The last closing price for Adicet Bio was $1.81. Over the last year, Adicet Bio shares have traded in a share price range of $ 1.10 to $ 7.50.

Adicet Bio currently has 43,164,522 shares outstanding. The market capitalization of Adicet Bio is $98.42 million. Adicet Bio has a price to earnings ratio (PE ratio) of -0.69.

ACET Latest News

More News

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience...

April 22 2024
Business Wire

Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

April 08 2024
Business Wire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

March 28 2024
Business Wire

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Expanded clinical pipeline into autoimmune diseases with U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug Application (IND) for ADI-001; initiation of Phase 1...

March 19 2024
Business Wire

Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

March 11 2024
Business Wire

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

February 29 2024
Business Wire

Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that...

February 05 2024
Business Wire

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

February 02 2024
Edgar (US Regulatory)

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it...

January 31 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

January 26 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.28-13.93034825872.012.251.668951891.94124822CS
4-0.66-27.61506276152.392.431.666821282.13939432CS
12-1.32-43.27868852463.053.621.6612786372.45878987CS
260.4838.41.253.771.111360842.46914839CS
52-4.34-71.49917627686.077.51.19003142.63164114CS
156-12.69-88.002773925114.4221.871.16506988.24751469CS
260-13.25-88.451268357814.9821.871.15615708.45627058CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

ACET Discussion

View Posts
Monksdream Monksdream 7 months ago
ACET new 52 week low
👍️0
Monksdream Monksdream 7 months ago
ACET new 52 week
👍️0
Monksdream Monksdream 7 months ago
ACET new 52 week low
👍️0
jondoeuk jondoeuk 7 months ago
Upcoming https://www.businesswire.com/news/home/20230927031162/en/Adicet-Bio-to-Present-Three-Scientific-Posters-Highlighting-its-Allogeneic-Gamma-Delta-T-Cell-Platform-and-Programs-at-the-Society-for-Immunotherapy-of-Cancer-SITC-38th-Annual-Meeting
👍️0
jondoeuk jondoeuk 10 months ago
Durability was always the big question for $ACET. Yesterday's dataset vs #ASH22 above https://t.co/PNIL1N2eUF— Jacob Plieth (@JacobPlieth) June 27, 2023
👍️0
masterofdisaster masterofdisaster 2 years ago
No sell off...guess I bet wrong
👍️0
TheFinalCD TheFinalCD 2 years ago
Phase 1's usually suck wind, I lost $80K on another one,

BIG lesson learned


👍️0
masterofdisaster masterofdisaster 2 years ago
It was weird....I think the MMs drop this at open to begin the sell off today.
👍️0
TheFinalCD TheFinalCD 2 years ago
whats weird is the rally after the offering


this market is upside down

topsy turvey

👍️0
masterofdisaster masterofdisaster 2 years ago
Bought puts today anticipating an offering and there it is.
👍️0
TheFinalCD TheFinalCD 2 years ago
13.20 low start

ACET
👍️0
crudeoil24 crudeoil24 2 years ago
14.20 in AH. Nice day for the clinical FDA phase I trial results.
👍️0
TheFinalCD TheFinalCD 2 years ago
thanks for creating the board

I was too lazy, did I say lazy, I meant bizy

https://ih.advfn.com/stock-market/NASDAQ/adicet-bio-ACET/stock-news/86734727/adicet-posts-early-stage-data-for-off-the-shelf-ca
👍️0
crudeoil24 crudeoil24 2 years ago
Adicet Bio shares are trading higher after the company announced interim data from its dose escalation Phase 1 study evaluating the safety and tolerability of ADI-001.
👍️0
crudeoil24 crudeoil24 2 years ago
Adicet Bio Inc. is a biotechnology company that is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. It is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The Company is focused on developing ADI-00x for solid tumors and hematological indications.
👍️0

Your Recent History

NASDAQ
ACET
Adicet Bio
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved